Truist Lifts PT on Teva Pharmaceutical Industries (TEVA) to $36 From $32

Core Insights - Teva Pharmaceutical Industries Limited (NYSE:TEVA) is recognized as one of the best-performing pharmaceutical stocks in 2025, with a price target increase from $32 to $36 by Truist, maintaining a Buy rating as the affordable medicines theme remains attractive heading into 2026 [1] Financial Ratings and Outlook - S&P Global Ratings upgraded Teva's long-term issuer credit rating to 'BB+' from 'BB' with a stable outlook, while Moody's affirmed a B1a rating with a positive outlook, indicating progress towards investment-grade status [2] - Teva's adjusted leverage decreased to 4.4x as of September 30, 2025, with expectations to drop below 4.25x in upcoming quarters, which is necessary for a higher rating [2] Business Performance - Teva has returned to revenue growth after five years of declines, supported by strong performance in branded medicines and stabilization in generics [3] - The company operates across geographical segments including the US, Europe, and International Markets, covering a full product portfolio that includes specialty, generics, and over-the-counter (OTC) products [4]